Publications

Publications Search

Search for publications by author
Search for publications by abstract keyword(s)

Reversion of BRCA1/2 germline mutations eetected in circulating tumor DNA from patients with high-grade serous ovarian cancer

Abstract

Purpose Germline BRCA1 or BRCA2 mutations in patients with high-grade serous ovarian cancer (HGSC) are associated with favorable responses to chemotherapy. However, secondary intragenic (reversion) mutations that restore protein function lead to clinically significant rates of acquired resistance. The goal of this study was to determine whether reversion mutations could be found in an unbiased manner in circulating cell-free DNA (cfDNA) to predict treatment response in HGSC. Patients and Methods Plasma and tumor samples were obtained from 30 patients with HGSC with either BRCA1 or BRCA2 germline mutation. Two cohorts were ascertained: patients with a malignancy before undergoing primary HGSC debulking surgery (n = 14) or patients at disease recurrence (n = 16). Paired tumor and plasma samples were available for most patients (24 of 30). Targeted amplicon, next-generation sequencing was performed using primers that flanked germline mutations, whose design did not rely on prior knowledge of reversion sequences. Results Five patients were identified with intragenic mutations predicted to restore BRCA1/2 open reading frames, including two patients with multiple independent reversion alleles. Reversion mutations were only detected in tumor samples from patients with recurrent disease (five of 16) and only in cfDNA from patients with a tumor-detected reversion (three of five). Findings from a rapid autopsy of a patient with multiple independent reversions indicated that reversion-allele frequency in metastatic sites is an important determinant of assay sensitivity. Abundance of tumor-derived DNA in total cell-free DNA, as measured by TP53 mutant allele frequency, also affected assay sensitivity. All patients with reversions detected in tumor-derived DNA were resistant to platin- or poly ADP ribose polymerase inhibitor-based chemotherapy. Conclusion Reversion mutations can be detected in an unbiased analysis of cfDNA, suggesting clinical utility for predicting chemotherapy response in recurrent HGSC.

Type Journal
ISBN 1527-7755 (Electronic) 0732-183X (Linking)
Authors Christie, E. L.; Fereday, S.; Doig, K.; Pattnaik, S.; Dawson, S. J.; Bowtell, D. D. L.
Responsible Garvan Author Prof David Bowtell
Publisher Name JOURNAL OF CLINICAL ONCOLOGY
Published Date 2017-04-20
Published Volume 35
Published Issue 12
Published Pages 1274-1280
Status Published in-print
DOI 10.1200/JCO.2016.70.4627
URL link to publisher's version https://www.ncbi.nlm.nih.gov/pubmed/28414925